21世纪经济报道记者 唐唯珂 广州报道 5月23日，科望医药集团 Elpiscience Biopharmaceuticals， Inc． （以下简称“科望医药”）向港交所递交招股书，拟在港交所主板上市。 科望医药此前多次尝试IPO。2021年公司向美国证监会（SEC）提交上市申请。2022年因中美监管环境变化、生物医药中概股估值低迷等因素撤回申请。2024年6月公司首次向港交所递交上市...
Source Link21世纪经济报道记者 唐唯珂 广州报道 5月23日，科望医药集团 Elpiscience Biopharmaceuticals， Inc． （以下简称“科望医药”）向港交所递交招股书，拟在港交所主板上市。 科望医药此前多次尝试IPO。2021年公司向美国证监会（SEC）提交上市申请。2022年因中美监管环境变化、生物医药中概股估值低迷等因素撤回申请。2024年6月公司首次向港交所递交上市...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.